Overview

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Status:
Recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

A clinical trial to assess the safety and efficacy of genetically-engineered, neoantigen-specific Tumor Infiltrating Lymphocytes (TIL) in which the intracellular immune checkpoint CISH has been inhibited using CRISPR gene editing for the treatment of Gastro-Intestinal (GI) Cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Intima Bioscience, Inc.
National Cancer Institute (NCI)

Collaborator:

Masonic Cancer Center, University of Minnesota

Treatments:

Aldesleukin
Cyclophosphamide
Fludarabine
Fludarabine phosphate
Interleukin-2
Vidarabine